http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shape factor s<sub>γ</sub> for shallow footings
Puzakov, Viktor,Drescher, Andrew,Michalowski, Radoslaw L. Techno-Press 2009 Geomechanics & engineering Vol.1 No.2
The results of FLAC3D-based numerical evaluation of the bearing capacity shape factor $s_{\gamma}$ are presented for square and rectangular footings on granular soils. The results confirm a peculiar effect found earlier by Zhu and Michalowski (2005), where for large values of internal friction angle, $s_{\gamma}$ exhibits a peak at some aspect ratio of the footing, and then decreases towards unity at large aspect ratios. The Zhu and Michalowski's results were derived using the finite element program ABAQUS, and the results presented in this note corroborate their earlier findings.
과산화수소 보존표백시 Silicate 대체 약품에 관한 연구
이상헌,정성욱,김성권,류재홍,Michalowski, R J 한국공업화학회 1997 응용화학 Vol.1 No.2
This study was carried out to investigate the effect of the Versenate PS as the peroxide bleach stabilizer in peroxide bleaching system. Currently, but, most peroxide bleach systems contain peroxide, caustic to activate the peroxide, and the use of a stabilizer such as sodium silicate to stabilize the peroxide during the actual bleaching. Therefore, to evaluate he degree to replace sodium silicate, the experiments of metal signature analysis, metal control by chelant(DTPA), caustic level optimization, and the addition of Versenate PS peroxide stabilizer were performed. The results shows that the only combination of Versenate PS and low sodium silicate provide the most effective peroxide bleaching.
Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
Kim, H K,Choi, I J,Kim, C G,Kim, H S,Oshima, A,Yamada, Y,Arao, T,Nishio, K,Michalowski, A,Green, J E Nature Publishing Group 2012 The pharmacogenomics journal Vol.12 No.2
<P>To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-throughput transcriptional profiling and array comparative genomic hybridization. Transcriptional profiling identified 917 genes that are correlated with poor patient survival after CF at <I>P</I><0.05 (poor prognosis signature), in which protein synthesis and DNA replication/recombination/repair functional categories are enriched. A survival risk predictor was then constructed using genes, which are included in the <I>poor prognosis signature</I> and are contained within identified genomic amplicons. The combined expression of three genes—<I>MYC</I>, <I>EGFR</I> and <I>FGFR2</I>—was an independent predictor for overall survival of 27 CF-treated patients in the validation set (adjusted <I>P</I>=0.017), and also for survival of 40 chemotherapy-treated gastric cancer patients in a published data set (adjusted <I>P</I>=0.026). Thus, combined expression of <I>MYC</I>, <I>EGFR</I> and <I>FGFR2</I> is predictive of poor survival in CF-treated metastatic gastric cancer patients.</P>